Travere Circle Logo

Retrophin Completes Acquisition of Orphan Technologies

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
Travere Circle Logo

Retrophin Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Read the press release >
Travere Circle Logo

Retrophin Announces Agreement to Acquire Orphan Technologies

SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
Travere Circle Logo

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined.  Read the press release >
Travere Circle Logo

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >
Black Women's Health Imperative logo

Eric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event

August 12, 2020 - the Black Women’s Health Imperative hosted a national webinar with its partner, the National Coalition of 100 Black Women, Inc. entitled “Our Health, Our Community: Mobilizing for the Survival of Black Women,” in partnership with EBONY.
PharmaVoice 100 logo

Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100

SAN DIEGO (August 3, 2020) – Retrophin,  Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president  and chief  executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Read the press release >
Travere Circle Logo

Retrophin Reports Second Quarter 2020 Financial Results

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter 2020 financial results and provided a corporate update. Read the press release >
Marshall Summar, M.D., CNRDI

Connecting More People to Optimal Rare Disease Care

,
An update on our partnership with Children's National Rare Disease Institute.
Rare Revolution Logo

Eric Dube, Ph.D., Interviewed by Rare Revolution

July 1, 2020 -- Our CEO and president Eric Dube, Ph.D., recently spoke with Rare Revolution Magazine about motivation, inspiration, challenges and hope.